Telix to acquire ITM in deal worth up to $2.35bn
Australia-based Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich in a transaction valued at up to $2.35bn. The deal …
Post
-
-
How DFE Pharma supports confident continuous manufacturing decisions
For pharmaceutical manufacturers, the question is whether a specific formulation can perform consistently under continuous conditions. That requires evidence on …
-
Sandoz and mAbxience agree on emicizumab biosimilar partnership
Sandoz and mAbxience have signed a licensing, development, manufacturing and commercialisation agreement covering a proposed emicizumab biosimilar candidate for haemophilia …
-
FDA hearing: psychedelics launch needs balanced regulation without limiting access
The area of psychedelic therapeutics has been rapidly growing in research and drug development with the advent of classical psychedelics …
-
FDA approves first gene therapy for Sanfilippo syndrome type A
The US Food and Drug Administration (FDA) has approved Ultragenyx’s gene therapy for Sanfilippo syndrome type A, marking the first …
-
FDA approves first gene therapy for Sanfilippo syndrome type A
The US Food and Drug Administration (FDA) has approved Ultragenyx’s gene therapy for Sanfilippo syndrome type A, marking the first …
-
Novo targets oral macrocycles with $1.4bn Orbis partnership
Novo has teamed up with macrocycle specialist Orbis Medicines in a deal worth up to $1.4bn, marking an effort by …
-
Ona Therapeutics to develop ADC with WuXi’s payload-linker platform
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker …
-
Roche agrees to $1bn deal with Dualitas for bispecific antibody research
Roche and Dualitas Therapeutics have entered a research collaboration and licence agreement that could reach a potential value of up …
-
The shrinking return on investment for Nordic innovation
Despite the region’s reputation as a thriving hub of innovation, Nordic biotechs are having a hard time funding the jump …
-
Novo taps Anthropic’s Claude to ‘supercharge’ R&D efforts
Novo will harness Anthropic’s AI assistant Claude to accelerate research and development (R&D) activities, as the drugmaker looks to regain …
-
Cellares and GenomeFrontier to assess automated GF-CART01 production
Cellares and GenomeFrontier Therapeutics have announced a collaboration to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01, …
-
Viatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy
Japan’s Ministry of Health, Labour and Welfare has approved Viatris’ Wakix (pitolisant) for excessive daytime sleepiness (EDS) related to obstructive …
-
Sling ropes in $123m for oral thyroid eye disease drug
Sling Therapeutics has raised $123m to propel its thyroid eye disease (TED) pill through a pivotal clinical trial. The funds, which …
-
Looking beyond short-term turmoil, Syngene is investing for the future
These are transitional times for Syngene, the Bengaluru, India-headquartered contract research, development, and manufacturing organisation (CRDMO). It already has an …
